Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 7/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31415638 | 0.77 | AVPR1A (0.44) | AVPR1AOPRD1OPRM1KCNH2 | |
| SCHEMBL30447969 | 0.77 | AVPR1A (0.50) | AVPR1AOPRD1OPRM1KCNH2 | |
| SCHEMBL30670269 | 0.75 | AVPR1A (0.49) | AVPR1AOPRD1OPRM1KCNH2 | |
| SCHEMBL26599110 | 0.75 | AVPR1A (0.49) | AVPR1AOPRD1OPRM1KCNH2 | |
| SCHEMBL1588637 | 0.74 | AVPR1A (0.48) | AVPR1AOPRD1OPRM1KCNH2 | |
| SCHEMBL30504151 | 0.74 | AVPR1A (0.39) | AVPR1AOPRM1KCNH2 | |
| SCHEMBL31185772 | 0.74 | AVPR1A (0.40) | AVPR1AOPRM1KCNH2 | |
| SCHEMBL29535632 | 0.74 | AVPR1A (0.60) | AVPR1AOPRD1 | |
| Hydrochloric Acid SCHEMBL16836155 | 0.73 | AVPR1A (0.47) | AVPR1AOPRD1OPRM1KCNH2 | |
| SCHEMBL30448121 | 0.73 | AVPR1A (0.53) | AVPR1AOPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856736-B1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-05-06 | — | — | EP | disclosed |
| US-12202816-B2 | Compounds as NADPH oxidase inhibitors | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2025-01-21 | — | — | US | disclosed |
| US-20220033379-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2022-02-03 | — | — | US | disclosed |
| EP-3856736-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | GenKyoTex Suisse SA (CH) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020065048-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | GENKYOTEX SUISSE SA (CH) | 2020-04-02 | — | — | WO | disclosed |
| EP-3628669-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | GenKyoTex Suisse SA (CH) | 2020-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202816-B2 | Compounds as NADPH oxidase inhibitors | CYBB, NOX1, NOX4 | AVPR1A 4644/4885OPRD1 2565/4885OPRM1 2929/4885 |
| US-20220033379-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CYBB, NOX1, NOX4 | AVPR1A 4551/4885OPRD1 2589/4885OPRM1 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.